(Q34783604)

4 August 2017

1 reference

title

Ovarian cancer: progress and continuing controversies in management (English)

1 reference

4 August 2017

1 reference

Charlotte Moss

1

1 reference

PubMed ID

12175685

4 August 2017

Stan B Kaye

series ordinal

2

1 reference

4 August 2017

1 September 2002

1 reference

European Journal of Cancer

4 August 2017

1 reference

4 August 2017

38

1 reference

4 August 2017

1701-1707

1 reference

4 August 2017

13

1 reference

The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. Gynecological Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer

4 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Specialist gynaecologists and survival outcome in ovarian cancer: a Scottish national study of 1866 patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

The integration of docetaxel into first-line chemotherapy for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Combination chemotherapy with carboplatin and docetaxel in the treatment of cancers of the ovary and fallopian tube and primary carcinoma of the peritoneum

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

First-line chemotherapy with epirubicin, paclitaxel, and carboplatin for advanced ovarian cancer: a phase I/II study of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Gemcitabine, platinum, and paclitaxel regimens in patients with advanced ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

A role for loss of p53 function in sensitivity of ovarian carcinoma cells to taxanes

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Treatment of advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Recent advances in the treatment of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Caelyx: phase II studies in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

A phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

A phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Activity of Gemcitabine in Patients with Advanced Ovarian Cancer: Responses Seen Following Platinum and Paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II study of gemcitabine in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II trial of pyrazoloacridine in recurrent platinum-resistant ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase I and pharmacologic study of liposomal lurtotecan, NX 211: urinary excretion predicts hematologic toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Meeting report on 8th International Symposium on Platinum and Other Metal Coordination Compounds in Cancer Chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Tumor targeting by conjugation of DHA to paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2802%2900161-2

7 January 2021

10.1016/S0959-8049(02)00161-2

Identifiers

DOI

1 reference

4 August 2017

1 reference

PubMed ID

12175685